Andexanet alfa

Andexanet alfa is a recombinant protein that is used as an antidote to reverse the anticoagulant effects of direct factor Xa inhibitors. It is a modified form of the human Factor X protein.

Etymology

The name "andexanet alfa" is derived from "antidote for Xa inhibitors" and "alfa" is a common suffix for recombinant proteins.

Mechanism of action

Andexanet alfa works by binding to direct factor Xa inhibitors, preventing them from inhibiting the activity of factor Xa. This allows the normal clotting process to resume.

Uses

Andexanet alfa is used to reverse the anticoagulant effects of direct factor Xa inhibitors in patients who are experiencing serious or uncontrolled bleeding or who require urgent surgery.

Side effects

Common side effects of andexanet alfa include nausea, vomiting, and headache. Serious side effects can include thrombosis and ischemia.

History

Andexanet alfa was approved for medical use in the United States in 2018. It is marketed under the brand name Andexxa by Portola Pharmaceuticals.

See also

• Anticoagulant
• Factor X
• Direct factor Xa inhibitors

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia